Recurring real-world drug use dashboards from a panel of
3,050 primary care physicians. Prescriptions, diagnoses, dosage and
prescription duration — under a single EDS Scientific Committee decision.
THIN (The Health Improvement Network) is the largest primary care database
in France. It compiles prescription data from 3,050 general practitioners
and specialists, faithfully capturing real-world prescribing practices.
Every prescription with the drug prescribed, daily dosage, prescription duration and quantity dispensed.
Consultation reasons and coded diagnoses (ICD-10), enabling every prescription to be contextualised by its therapeutic indication.
Analysis of actual daily dosage and prescribed prescription duration — key real-world usage indicators.
Age, sex and comorbidities of patients, enabling sub-population analyses and characterisation of prescribing profiles.
10-year patient history enabling analysis of therapeutic trajectories, treatment switches and treatment initiations.
Each THIN dashboard is built around a defined therapeutic scope,
with standardised indicators assessing real-world drug use.
Number of prescriptions, first-prescription rates, monthly volume trends by molecule and therapeutic class.
Breakdown of prescriptions by ICD-10 diagnosis, identification of off-label indications and analysis of associated comorbidities.
Average prescribed daily dosage vs. recommended dosage, analysis of dose adjustments according to patient profiles.
Distribution of prescription durations, analysis of renewals and therapeutic coverage over time.
Analysis of switches between molecules, successive lines of treatment and concomitant drug combinations.
Prescription market share by molecule, competitive evolution and prescriber profile by specialty and region.
THIN dashboards meet the needs of Medical Affairs,
Market Access, HEOR and pharmaceutical Marketing teams.
Monthly monitoring of prescribed volumes, market share and competitive dynamics at the primary care prescription level.
Comparison of real-world dosages and prescription durations against SmPC recommendations. Identification of atypical practices by prescriber profile.
Demographic and diagnostic profile of patients on treatment, comorbidity analysis and real-world target population characterisation.
Access to THIN data is granted under a single decision issued by the EDS Scientific
Committee (Health Data Warehouse). This decision covers all recurring dashboards
produced on the same database, guaranteeing a stable and simplified legal
framework for monitoring real-world drug use.
A process governed by the EDS, with recurring monthly delivery from the first decision granted.
Definition of therapeutic areas, priority indicators and the scope of the request.
1 week
Preparation and submission of the application to the EDS Scientific Committee to obtain the single access decision.
4-8 weeks
Development of custom indicators and visualisations validated with your teams.
2-4 weeks
Automatic monthly update of your dashboards with the latest prescription data.
Ongoing
Contact our team to scope your needs and initiate
the process with the EDS Scientific Committee.